David R. Gandara, MD, discusses the impact of immunotherapy on the tumor microenvironment in lung cancer. Website: Dr. David Gandara Describes Exciting New Lung Cancer Research
David Gandara, MD, professor, Division of Hematology/Oncology, University of California Davis Comprehensive Cancer Center, Living Room Highlights: Second Opinion Appointments Using Telehealth David Gandara's profile, publications, research topics, and co Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara DR, Koczywas M
Dr. David Gandara on Thymidylate Synthase Expression in ALK-Positive Non-Small Cell Lung Cancer Dr. Gandara, Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, shares the
David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Dr. Gandara, Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, discusses Rapid Response Living Room - Lung Cancer is Not Taking a Back Seat, Care Must Go On - 05/05/20
David Gandara, MD, Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, tell In the first installment of the series, the moderator, David R. Gandara, MD, provides an overview of the topics that will be discussed David Gandara, MD, from the University of California, Davis, CA discusses the results of the OAK trial (NCT02008227) and how
Dr. Gandara on the Impact of Immunotherapy on the Tumor Microenvironment in Lung Cancer Dr. Gandara Discusses the OAK Trial for Lung Cancer
Dr. Gandara, Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, In his second visit to the Lung Cancer Living Room, Dr. David Gandara of UC Davis Comprehensive Cancer Center, discusses Diagnostic Advances Shape Treatment Decisions in Lung Cancer
During the ASCO meeting, David Gandara, M.D., Professor of Medicine, Director, Thoracic Oncology Program, UC Davis David R. Gandara, MD, is the director of the Thoracic Oncology Program, professor of medicine, and senior adviser to the director at the University of David Gandara | UC Davis Profiles
David Gandara, MD - Professor at UC Davis Comprehensive Cancer Dr. David Gandara of UC Davis visits the Living Room to discuss your unique molecular fingerprint and how we can use this
David Gandara, MD, current thinking regarding testing for PD-L1 biomarker in NSCLC patients Dr. Herbst on the International Lung Cancer Congress Dr. David Gandara on Patient Selection for Molecular Testing in Lung Cancer
David R. Gandara, MD, has been appointed chief medical officer (CMO) of the International Society for liquid biopsy (ISLB). David Gandara (@drgandara) - Posts - Medical Oncologist & clinical-translational researcher in lung cancer. Co-Director-Center for Experi. Combining CTLA-4 Agents With PD-1/PD-L1 Agents in Lung Cancer
Increasing treatment options for NSCLC Dr. Gandara on the Utility of TMB in NSCLC
David Gandara, MD, is a clinician-scientist and lung cancer specialist internationally recognized for his expertise in thoracic cancers, cancer drug David R. Gandara, MD, professor of Medicine, University of California Davis Comprehensive Cancer Center, discusses the initial Dr. Gandara on Strategies for Overcoming KRAS Mutations in Lung Cancer
David R. Gandara, MD, discusses drug sequencing as a result of Keynote 189 and 42 results David Gandara, MD, discusses considerations when choosing between immunotherapy and chemotherapy
Dr. Gandara on the Heat Shock Protein 90 Inhibitor Ganetespib David R. Gandara, MD, invites you to the 23rd Annual International Lung Cancer Congress® July 28 - July 30, 2022. Join PER®
David Gandara, MD from the University of California, Davis, CA discusses the recent change in the treatment landscape of THE LUNG CANCER LIVING ROOM™ - PERSONALIZING YOUR CARE - DR. DAVID GANDARA - FEB. 19, 2013 David R. Gandara, MD - ILCN.org (ILCN/WCLC)
Dr. Gandara on Online Treatment Decision Tool for Lung Cancer (Edited version) In this week's Rapid Response episode of The Lung Cancer Living Room, our host Danielle Hicks and guest, Dr.
David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program, David R. Gandara, MD, discusses exciting new developments in lung cancer here at ASCO 2018
David Gandara, MD, discusses pembrolizumab vs docetaxel for previously treated NSCLC patients Rapid Response Living Room: Lung Cancer is Not Taking a Backseat - Dr. David Gandara - May 5, 2020
David Gandara, M.D., Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, David R. Gandara, MD, Appointed Chief Medical Officer (CMO) of International Society of Liquid Biopsy 2021 Virtual Meeting
Introduction: Advances and Issues in Non-Small Cell Lung Cancer Topic: Lung Cancer is Not Taking a Backseat, Neither Are We – Care Must Go On Speaker: David R. Gandara, MD - Professor of
David R. Gandara, MD, on continuing pemextrexed maintenance David R. Gandara, M.D. is affiliated with UC Davis Health System and specializes in Lung Disease, Hematology/Oncology, Internal Medicine, Dr. Gandara, Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, on what will
David Gandara, MD,, discusses PD-L1 expression and selecting the appropriate agent in NSCLC patients Dr. Gandara is Professor Emeritus at the University of California Davis Comprehensive Cancer Center (UCDCCC) where he is Director of Thoracic Oncology.
In this week's Rapid Response episode of The Lung Cancer Living Room, our host Danielle Hicks and guest, Dr. David Gandara In today's episode, we had the pleasure of speaking with David R. Gandara, MD, about biomarker testing in lung cancer. Dr Gandara is the chief
David R. Gandara, MD, director, Thoracic Oncology Program, and professor, UC Davis Comprehensive Cancer Center, discusses Roy S. Herbst, MD, PhD, Chief of Medical Oncology, Yale Comprehensive Cancer Center, describes the 12th International Lung Living Room Highlights: Determining Whether to Use a Solid or Liquid Biopsy in the Time of COVID
Topic: Lung Cancer is Not Taking a Backseat, Neither Are We – Care Must Go On Speaker: David R. Gandara, MD Professor of Dr. Gandara Discusses the Future of Clinical Trial Designs David R. Gandara, MD, Director, Thoracic Oncology Program, University of California, Davis Comprehensive Cancer Center,
David R. Gandara, MD, shares the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC Dr. Gandara on Measuring TMB in NSCLC David R. Gandara, MD, on what will change about patient selection as a result of Keynote 42
David R. Gandara, MD, on whether Keynote 189 impacted view of PDL-1 expression and patient selection Dr. Gandara on Recent Advancements in Field of Lung Cancer
Dr. Gandara on Treatment Options for Squamous Cell NSCLC PD-L1 agents in the treatment of NSCLC
"Back to the Future": Developments in Immunotherapy with David Dr. Gandara on the MYSTIC Trial for Lung Cancer David Gandara, MD, discusses the positioning of Cyramza post platinum therapy in NSCLC patients
David Gandara, MD, talks about the potential impact of immunotherapy in 1st line NSCLC Dr. Gandara Discusses Clinical Implications of the FLAURA Study in NSCLC
ABD'li profesör: Ölümcül kanserleri kronik hastalıklara çevirebiliyoruz Dr. David Gandara Discusses Multiplexing Molecular Tests for NSCLC David Gandara, MD, UC Davis Comprehensive Cancer Center, Sacramento, CA, gives an overview of the International Society of
The Lung Cancer Living Room™ - Your Molecular Fingerprint - David Gandara, MD - Nov. 2011 David Gandara (@drgandara) / Posts / X Initial Results of the Ongoing MYSTIC Trial in Stage IV Lung Cancer
David R. Gandara, M.D. for UC Davis Health Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing
ABD Kaliforniya Üniversitesi'nden onkolog Prof. Dr. David Gandara, "Eskiden ölümcül kanser dediğimiz kanserleri artık diyabet Dr. Gandara, Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center on whether
Lung Cancer Living Room - 05-05-20 David R. Gandara, M.D. - Lung Disease - UC Davis Health System David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, University of California Davis
David R. Gandara, M.D., UC Davis Comprehensive Cancer Center, discusses how diagnostic and therapeutic changes are Dr. Gandara is Professor and Director of Thoracic Oncology at UC Davis Comprehensive Cancer Center, Sacramento, US. He is former President of IASLC.
Dr. Gandara Discusses Third-Generation EGFR TKIs Dr. David Gandara Spotlights the Giants of Cancer Care
David R. Gandara, MD, invites you to the 23rd Annual International Lung Cancer Congress® 7/28-7/30 Dr. Gandara on How Lung-MAP Trial is Optimal for Patient Care
Dr. David Gandara is a clinician-scientist and lung cancer specialist internationally recognized for his expertise in thoracic cancers (lung cancer), cancer Dr. Gandara on Practice-Changing Studies in Lung Cancer Inductees